Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $38,593.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the transaction, the insider now owns 176,952 shares in the company, valued at $2,919,708. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total value of $34,354.25.
• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total transaction of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.

Hims & Hers Health Price Performance

HIMS stock opened at $16.90 on Friday. The company has a market capitalization of $3.63 billion, a P/E ratio of -1,690.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The firm’s fifty day simple moving average is $17.54 and its 200-day simple moving average is $17.04.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s revenue was up 51.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.03) earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HIMS. Victory Capital Management Inc. boosted its position in Hims & Hers Health by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after purchasing an additional 3,429 shares in the last quarter. Diversify Advisory Services LLC acquired a new stake in Hims & Hers Health during the first quarter valued at $701,000. Sei Investments Co. grew its position in Hims & Hers Health by 206.9% during the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after buying an additional 37,890 shares during the period. Quantbot Technologies LP increased its holdings in Hims & Hers Health by 3,444.9% in the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after buying an additional 208,621 shares in the last quarter. Finally, Quadrature Capital Ltd raised its position in shares of Hims & Hers Health by 494.2% in the first quarter. Quadrature Capital Ltd now owns 201,043 shares of the company’s stock worth $3,108,000 after acquiring an additional 167,211 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Jefferies Financial Group raised their price target on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Finally, TD Cowen increased their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.